Rosiglitazone has been proposed as a treatment strategy for type 2 diabetes mellitus (T2DM), and it could provide robust glucose-lowering capability with risk of cardiovascular events. We thus performed a systematic review and meta-analysis of controlled trials to assess the effect of this treatment on glycaemic control and cardiovascular events in patients with T2DM. We systematically search PubMed, Embase, and the Cochrane Central Register of Controlled Trials comparing rosiglitazone to other anti-diabetic treatments. These studies included randomised controlled trials (RCTs), cohort studies, and case-control studies that had treatment with at least six months of follow-up in patients with T2DM. We aimed to evaluate the long-term effect on cardiovascular risk of rosiglitazone compared with a basal insulin drug. The main outcomes included myocardial infarction, heart failure, stroke, cardiovascular mortality, and all-cause mortality. We included 11RCTs and four observational studies involving 20,079 individuals with T2DM allocated to rosiglitazone and a similar number to comparison groups of which only five compared rosiglitazone with placebo and collected data on cardiovascular outcomes. Among patients with T2DM, rosiglitazone is associated with a significantly increased risk of heart failure, with little increased risk of myocardial infarction, without a significantly increased risk of stroke, cardiovascular mortality, and all-cause mortality compared with placebo or active controls. Alternative methods to reduce the uncertainty in long-term pragmatic evaluations, inclusion of rosiglitazone in factorial trials, publication of cardiovascular outcome data from adverse event reporting in trials of rosiglitazone and a cardiovascular endpoint trial of rosiglitazone among people without diabetes. 
Introduction
Type 2 diabetes mellitus is considered an epidemic in the world [1] . Complications of diabetes included stroke, blindness, kidney failure, and lower-extremity amputations; the most common developments are heart disease [2] , stroke [3, 4] , and associated metabolic abnormalities, such as lipid abnormalities and chronic  vascular inflammation [5] , which are significant cardiovascular risk factors. The treatment options for diabetic patients are limited and the costs are high. To meet the demand for newer and more effective drug treatments for T2DM, the prescribing medication to lower glucose among people with T2DM aims to reduce the symptoms of hyperglycaemia and the risk of macrovascular complications. Rosiglitazone is one member of the thiazolidinedione class of peroxisome proliferation-activated receptor gamma (PPAR-γ) antidiabetic agents, mainly metabolised by liver, which have reduced insulin resistance so as to effectively control blood glucose [6] , which is also a key factor in hyperglycaemia in patients with T2DM. However, subsequent randomised trials evaluating the effects of intensive treatment for the regulation of blood glucose have highlighted concerns about adverse effects, in particular hypoglycaemia and mortality [7] , and demonstrated inconsistent findings for risk of macrovascular complications [8] . Clinical data show that rosiglitazone can improve insulin sensitivity, and it is an effective treatment for glycated haemoglobin production and fasting, with significant reductions in plasma glucose for T2DM [9, 10] . Synchronously, rosiglitazone suggests potentially beneficial effects on overall cardiovascular risk; it can reduce blood pressure, improve vascular endothelial dysfunction and lipid metabolism disorders [9, 11, 12] . In addition, the other benefits have included reduced serum matrix metalloproteinases-9, C-reactive protein [13, 14] , and serum levels [15] . There have been some reports of severe adverse drug reactions, such as heart failure, in the early stages of rosiglitazone treatment [16] .
The cardiovascular safety of rosiglitazone in patients with diabetes has become a major concern [17] . Since then, several articles have reviewed the efficacy of rosiglitazone for the treatment of T2DM in controlled trials on cardiovascular safety [18] . There is no enough clinical trial evidence that rosiglitazone-induced glycaemic control leads to a reduction in the macrovascular complications of T2DM. Therefore, our objective was to qualitatively and quantitatively evaluate the benefits (e.g. myocardial infarction and stroke) and risks (e.g. heart failure, cardiovascular mortality, all-cause mortality) of rosiglitazone therapy in patients with T2DM. We have conducted a systematic review and meta-analysis to date.
Material and methods
We undertook a systematic review and meta-analysis in accordance with the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) [19] and the Meta-Analysis of observational Studies in Epidemiology (MOOSE) [20] .
Search strategy
We searched PubMed (1966 to 17 May 2017), EMBASE,  and the Cochrane Central Register (1966 to 17 May 2017) for RCTs and observational studies using the search words rosiglitazone or thiazolidinediones or TZDs and myocardial infarction or cardiovascular or stroke or heart failure and type 2 diabetes, or T2DMs, and limited our search to investigations that were randomised clinical trials involving humans. We also completed the papers with meta-analysis and rosiglitazone in the title. We restricted the search to studies in humans and clinical trials using filters provided by PubMed and EM-BASE. There was no language restriction. We retrieved further information by a manual search of references from recent reviews and relevant published original studies. Finally, we manually screened the reference list of a recent systematic review of cardiovascular endpoint trials of glucose-lowering medication [21] .
The included trials had to state their intention to monitor cardiovascular adverse events in the "Aims" or "Methods" section, and to explicitly report data (including zero events) on MI, HF, stroke, and cardiovascular mortality. The studies also included a cohort or case-control design that enrolled participants with T2DM. The inclusion criteria for trials were as follows: 1. rosiglitazone treatment of at least six months duration; 2. study participants with T2DM; 3. rosiglitazone as the intervention drug vs. a control, which could be placebo or other oral hypoglycaemic drugs.
Study selection
Trials were identified and subjected to the following inclusion criteria: controlled trial among adults with T2DM comparing any dose and preparation of oral rosiglitazone with no intervention, or with placebo and reporting mortality or a cardiovascular outcome (cardiovascular death, myocardial infarction, stroke, or HF) as a primary or secondary outcome. Published reports were reconciled with trials in the Prospective Register of Systematic Reviews register when possible. We also extracted the following data from each selected study: total number of participants, age, sex, trial duration, mean HbA1c, body weight, FPG and any cardiovascular adverse events were subjected to adjudication to assess the adverse drug reaction. We excluded quasi-experimental studies and crossover, patients with NYHA class II-III heart failure, studies including children, pregnant women, and people with impaired glucose tolerance, and follow-up was less than six months.
Statistical analysis
We assessed rosiglitazone on five outcomes: myocardial infarction, heart failure, stroke, cardiovascular mortality,
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and all-cause mortality. For analysis of cardiovascular events of participants, we calculated an overall relative risk (RR). For categorical outcomes we also calculated pooled estimates of the relative risk with a randomeffects model. In the analyses of each outcome, we performed pre-planned sensitivity analyses restricted to trials that compared PPAR-γ agonist treatment to basalbolus insulin regimens. The risks of cardiovascular were more significant for rosiglitazone treatment.
We assessed the possibility of publication bias by constructing a funnel plot of each trial's effect size against the standard error (appendix). The assessed funnel plot asymmetry using Begg and Egger tests, and defined significant publication bias as P < 0.1. We use the Cochran Q test to assess heterogeneity between studies. We also did I2 testing to assess the magnitude of the cardiovascular events between studies, with values greater than 50% regarded as being indicative of moderate-to-high heterogeneity. These data were processed using Review Manager (RevMan), version 5.3 (The Nordic Cochrane Centre, Copenhagen, Denmark) to calculate relative risks (RRs).
We assessed the risk of publication bias by producing a funnel plot for all-cause mortality. We performed sensitivity analyses to explore the influence on effect size of statistical models, trial duration, and adjudication of cardiovascular events.
Results
We identified 2994 potentially relevant studies for our analysis (Fig. 1) . Following screening of titles and abstracts, we reviewed the full text of 878 articles and included 15 trials that met all the inclusion criteria for the meta-analysis. The full text stage that absence of the collection of data or clinical data for cardiovascular events were excluded. The characteristics of the included studies are shown in Table I . Studies were reported between 2002 and 2015. Four of 15 studies were observational studies, and the other studies were randomised, controlled trials. Two studies were open-label [42, 44] , and of the seven placebo-controlled trials, 10 included other glucose-lowering drugs. We identified five trials including 3136 patients allocated to rosiglitazone, which simply compared rosiglitazone with placebo and collected data on cardiovascular outcomes [36, 37, 39, 46, 47] . In total, 20,079 patients with type 2 diabetes were allocated to rosiglitazone, and a similar number to comparison groups, in the included studies. Duration of follow-up ranged from six to 72 months; three studies followed patients up for more than four years [6, 34, 36] . No studies were assessed as having low risk of bias (Fig. 2) . Participants' mean age ranged from 50 to 64.3 years and exceeded 60 years in six studies [34, 36, 37, 38, 43, 47] , and the RCT participants tended to be overweight/ /obese (average baseline BMI ranged from 27.9 to 34.1 kg/m 2 ), with longstanding (average duration ranged from 0 years in one study [41] to 11.5 years [38] and poorly controlled diabetes [HbA1c was less than 8%] in seven studies [6, 35, 41, 42, [45] [46] [47] and ranged from 6.8% to 9.3%; average baseline FPG was less than 150 mg/dl in three studies [39, 41, 45] , and unclear in four studies and ranged from 105.5 to 184 mg/dl). The RRs for our pooled analyses of the effects of rosiglitazone for MI, heart failure, stroke, cardiovascular mortality and all-cause mortality are shown in Figure 3 . Data on cardiovascular events and mortality in the included trials are shown in Table II . The appendix also shows the assessment of risk of bias in the trials. Eleven randomised, controlled trials reported adequate randomisation, none was stopped early, eight were multicentre, five studies did not specify whether data collectors and outcome assessors were masked to treatment allocation, and only three were not funded by industry.
The effect of rosiglitazone on risks of heart failure ( Fig. 3 ), myocardial infarction (Fig. 4) , stroke ( Fig. 5 ), cardiovascular death (Fig. 6) , and all-cause mortality ( Fig. 7) are shown. All outcomes, except for the risk of heart failure, favoured rosiglitazone, with limited heterogeneity between studies, but none achieved statistical 
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significance. Meta-analysis showed that rosiglitazone treatment increased the risk of cardiovascular events (Table III) .
Heart failure
The data from 12 trials involving 52,394 patients, and nine RCT trials showed that the RR of heart failure with rosiglitazone significantly increased compared with placebo or active controls (175/7227 vs. 116/8672; RR 1.71; 95% CI 1.36-2.15; P < 0.001) (Fig. 3) . There was no evidence of substantial statistical heterogeneity among the trials (I2 = 9%). The three observational studies trials showed that the RR of heart failure with rosiglitazone were (320/10032 vs. 967/26463; RR 1.84; 95% CI 1.60-2.13; P < 0.001), There was significant statistical heterogeneity among the trials (I2 = 87%).
MI
From the data from 12 trials involving 72,151 patients, nine RCT trials showed that the RR of myocardial infarction with rosiglitazone did not significantly increase compared with placebo or active controls (157/7249 vs. 159/8696; RR 1.12; 95% CI 0.90-1.39; P = 0.30) (Fig. 4) . There was no evidence of substantial statistical heterogeneity among the trials (I2 = 0%). The three observational trials showed that the RR of myocardial infarction with rosiglitazone was 216/11601 vs. 1367/44605; RR 1.36; 95% CI 1.17-1.58; P < 0.001. There was no evidence of substantial statistical heterogeneity among the trials (I2 = 0%).
Stroke
From the data from seven RCT trials involving 16,220 patients, nine RCT trials showed that the RR of stroke with rosiglitazone did not significantly increase compared with placebo or active controls (152/7387 vs. 185/8833; RR 0.91; 95% CI 0.74-1.13; P = 0.39) (Fig. 5) .
There was no evidence of substantial statistical heterogeneity among the trials (I2 = 0%).
Cardiovascular mortality
From the data from 12 trials involving 29,105 patients, 11 RCT trials showed that the RR of cardiovascular mortality with rosiglitazone was not significantly increased compared with placebo or active controls (n = 112/7489 vs. 127/8933; RR 0.93; 95% CI 0.72-1.19; P = 0.55) (Fig. 6 ). There was no evidence of substantial statistical heterogeneity among the trials (I2 = 0%). One observational study trials showed that the RR of cardiovascular mortality with rosiglitazone was (30/745 vs. 418/11938; RR 1.15; 95% CI 0.80-1.65; P = 0.45).
There was no evidence of substantial statistical heterogeneity.
All-cause mortality
From the data from 11 trials involving 28,957 patients, 10 RCT trials showed that the RR of all-cause mortality with rosiglitazone was not significantly increased compared with placebo or active controls (222/7415 vs. 254/8859; RR 1.00; 95% CI 0.84-1.19; P = 0.99) (Fig. 7) . There was no evidence of substantial statistical heterogeneity among the trials (I2 = 0%).
The observational study trials showed that the RR of all-cause mortality with rosiglitazone was 40/745 vs. 734/11938; OR 0.87; 95% CI 0.64-1.19; P = 0.39.
There was no evidence of substantial statistical heterogeneity. Summary estimates of 11 RCTs were based on a small number of events: 112 cardiovascular deaths in nine studies, 157 myocardial infarctions in nine studies, 175 heart failure events in seven studies, and 151 strokes in six studies. Two studies [34, 42] contributed the majority of data in the summary estimates, with weights of 61.7% for myocardial infarction, 81.4% for stroke, and 75% Abbreviation: Ros, Rosiglitazone; Met, Metformin; Plac, Placebo; Ros, Rosiglitazone; Sul, Sulfonylurea; Con, Control for heart failure. We undertook a sensitivity analysis replacing data from the longer-term follow-up of the two studies [33, 41] with the original published data [6] . This led to small changes in the pooled estimates that more strongly favoured rosiglitazone for risk of heart failure and the risk of myocardial infarction. The funnel map (Fig. 8) does not show that rosiglitazone has a risk of increasing mortality.
Sensitivity analysis
We performed sensitivity analyses using pooling methods and statistical models regarding heterogeneity, and the cardiovascular events (heart failure, MI, and stroke) were similar. There was little or no heterogeneity in the metaanalysis of cardiovascular events, suggesting a consistent treatment effect. After excluding the trial with the smallest number of participants, observational studies, and shortest follow-up, the analysis of heart failure (RR 2.14; 95% CI 1.49-3.05; P < 0.001), MI (RR 1.35; 95% CI 1.00-1.83; P = 0.05), and stroke (RR 0.96; 95% CI 0.76-1.22; P = 0.74) with rosiglitazone from the three large trials of similar duration was similar.
Discussion
The meta-analysis included 11 randomised controlled trials and observational studies with over 20,000 participants with T2DM allocated to rosiglitazone. Though it was uncertainty about whether it reduces risk of 
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cardiovascular disease. In this review compared with a control group, we have summarised the adverse effects of the rosiglitazone group as an approximate doubling of the risk of heart failure, with an increase in the risk of the other cardiovascular events (e.g. MI and stroke), cardiovascular mortality, and all-cause mortality without any difference. In the results there are only five randomised, controlled cardiovascular endpoint trials simply comparing rosiglitazone with placebo among patients with type T2DM. We found that rosiglitazone significantly increases the risk of heart failure and MI compared with other basal-bolus insulin regimens. These data show rosiglitazone and basal insulin combination treatment as a therapeutic strategy that can improve the management of T2DM. We analysed some cardiovascular events and used sensitivity analysis to adjudicated cardiovascular events that did not change the direction or magnitude of the effect. Two previous meta-analyses showed that the risk of MI was significantly increased by rosiglitazone [22, 23] . One involving 42 RCTs with 14,237 participants determined the incidence of MI in the rosiglitazone compared with controls (RR 1.31; 95% CI 1.01-1.70) [22] . The other analysis involving 42 RCTs with 28,443 patients reported an increase in the risk of MI with rosiglitazone compared with controls (RR 1.43; 95% CI 1.03-1.98; P = 0.03) [23] . Our analyses included long-term trials showing that the RR estimate of 1.41 for MI is similar to the OR estimate of 1.43 obtained by two authors. A recent analysis reported that TZDs did not increase the risk of hypoglycaemia compared with controls; a possible mechanism for this is the fact that TZDs are mainly metabolized by the liver [17] . Several previous studies [24, 25] found, compared with active drugs, that metformin, rosiglitazone, and sulfonylurea had similar hypoglycaemic effect, which explained that the changes of HbA1c and FPG had no statistical significance. Our findings were consistent with published meta-analyses that found that rosiglitazone can increase the risk of MI, stroke, or heart failure [8, 26] .
All trials of the analyses suggested the possibility of bias or lack of information to evaluate the risk of bias. Most data for this review came from previous data [6, 39, 42, 43] that lacked recent experimental data. One study [35] shown patients with the bypass angioplasty revascularisation investigation T2DM, that had some limited for analysis. The data from the four observational studies [35, 36, 43, 44] were rather heterogeneous. Those were seminal trials concerning the effectiveness and safety of treatments for T2DM, albeit exhibiting a number of previously discussed limitations that might influence interpretation [27] . The analyses lack of placebo and double-blinding, 'subgroup' nature, lack of statistical significance of the update threshold, possible differences in the management of other cardiovascular risk factors between groups, and control of blood glucose levels in the control group the current standard is poor. In short, the research limitations included: 1. limited data on random trials, and inaccurate risk ratio. 2. Wide confidence intervals due to the small numbers. 3. Whether MI and heart failure have information on the time was unavailable, which affects the calculation of hazard ratios. 4. Whether patients with cardiovascular disease and severity before experimental study, which have consequences for the outcome.
Rosiglitazone can reduce the blood sugar in people with T2DM by increasing the sensitivity of the tissue to insulin. Rosiglitazone may increase the incidence of oedema, which raises concerns about the use of these drugs in heart failure patients [28] . In addition to the hypoglycaemic effect, rosiglitazone is beneficial to the cardiovascular system by activating the body fluid, thrombus, and PPAR receptors on the endothelium [29] . Studies have suggested that rosiglitazone and pioglitazone are used in patients with heart failure or worsen, especially those that are in combination with insulin [30] . In the management of T2DM, the attainment of glycaemic targets is compromised by the limitation of available treatment. With some anti-diabetic treatments (e.g. sulfonylureas, insulin), there is an increased risk of hypoglycaemia as glucose concentrations approach the desired normal range. Other drugs (e.g. rosiglitazone, insulin) are associated with weight gain, an undesirable effect in patients with T2DM [31] .
The use of cardio-protective drugs to control cardiovascular risk factors during the study may help reduce the risk of rosiglitazone damage. The cardiovascular differences between rosiglitazone and pioglitazone may be partly explained by different effects of lipids and lipoproteins, granules, and subclasses [32, 33] . If the excessive adverse effects of MI are mediated by LDL cholesterol and triglyceride rosiglitazone, it is possible to have sufficient fat to control statins, which can reduce the risk of MI. Aspirin also can reduce the risk of diabetes and coronary heart disease. The use, among patients with hypertension and diabetes, of angiotensin converting enzyme inhibitors or angiotensin receptor blockers may have an impact on cardiovascular adverse ketone, which can recede the protection of the heart. So the analysis should be based on the hierarchical use of these drugs as additional clinical data at lower risk of heart failure using Rogge column.
Although further research is needed to determine the best treatment method in practical application, our results clearly illustrate the effect of rosiglitazone on the cardiovascular system in the clinical treatment of patients with T2DM. The analyses have potential 
